The FDA rolled out an expedited Investigational New Drug (IND) pilot program intended to reduce bottlenecks in early development submissions. The IND pilot is framed as part of HHS efforts to onshore clinical trials and aims to move certain submission steps in parallel using more risk-appropriate judgment—while retaining the agency’s review standards and timelines.